Personalis (NASDAQ:PSNL) CEO Sells $1,315,000.00 in Stock

Personalis, Inc. (NASDAQ:PSNL) CEO Christopher Hall sold 100,000 shares of the firm’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $13.15, for a total transaction of $1,315,000.00. Following the completion of the transaction, the chief executive officer owned 235,986 shares of the company’s stock, valued at approximately $3,103,215.90. The trade was a 29.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Personalis Price Performance

PSNL stock opened at $13.02 on Monday. Personalis, Inc. has a 52-week low of $3.84 and a 52-week high of $13.37. The company’s 50 day simple moving average is $8.42 and its 200-day simple moving average is $8.28. The firm has a market capitalization of $1.36 billion, a P/E ratio of -12.76 and a beta of 2.27.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The firm had revenue of $15.47 million during the quarter, compared to analyst estimates of $14.48 million. Sell-side analysts predict that Personalis, Inc. will post -1.06 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of PSNL. Caitong International Asset Management Co. Ltd increased its holdings in Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after buying an additional 1,479 shares during the last quarter. Legal & General Group Plc acquired a new stake in Personalis in the second quarter valued at approximately $30,000. International Assets Investment Management LLC bought a new stake in Personalis in the fourth quarter worth approximately $31,000. BNP Paribas Financial Markets grew its position in Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after acquiring an additional 5,177 shares in the last quarter. Finally, Focus Partners Wealth acquired a new position in shares of Personalis during the 1st quarter worth $47,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Wall Street Zen downgraded Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. BTIG Research decreased their price objective on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Finally, Morgan Stanley lowered their target price on Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.00.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.